A5003236308- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Immune cells in cancer
- Nanoplatforms for cancer theranostics
- Glioma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Nutrition, Genetics, and Disease
- Dietary Effects on Health
- Health, Environment, Cognitive Aging
- Inflammation biomarkers and pathways
- Adipose Tissue and Metabolism
- T-cell and B-cell Immunology
- Histone Deacetylase Inhibitors Research
- interferon and immune responses
- Sleep and related disorders
- Obstructive Sleep Apnea Research
- Circadian rhythm and melatonin
- Sleep and Wakefulness Research
University of Colorado Anschutz Medical Campus
2020-2022
University of Colorado Boulder
2019-2021
Abstract Objectives While much of the research concerning factors associated with responses to immune checkpoint inhibitors (ICIs) has focussed on contributions conventional peptide‐specific T cells, role unconventional such as mucosal‐associated invariant (MAIT) in human melanoma remains largely unknown. MAIT cells are an abundant population innate‐like expressing a semi‐invariant T‐cell receptor restricted MHC class I‐like molecule, MR1, presenting vitamin B metabolites derived from...
Abstract Study Objective Identify small molecule biomarkers of insufficient sleep using untargeted plasma metabolomics in humans undergoing experimental sleep. Methods We conducted a crossover laboratory study where 16 normal-weight participants (eight men; age 22 ± 5 years; body mass index < 25 kg/m2) completed three baseline days (9 hours opportunity per night) followed by 5-day (5 and adequate conditions. Energy balanced diets were provided during baseline, with ad libitum energy...
Measuring individual circadian phase is important to diagnose and treat rhythm sleep-wake disorders misalignment, inform chronotherapy, advance science. Initial findings using blood transcriptomics predict the marker dim-light melatonin onset (DLMO) show promise. Alternatively, there are limited attempts metabolomics DLMO no known omics-based biomarkers offset (DLMOff). We analyzed human plasma metabolome during adequate insufficient sleep DLMOff one sample. Sixteen (8 male/8 female) healthy...
Background: Adrenal gland metastases (AGMs) are common in advanced-stage melanoma, occurring up to 50% of patients. The introduction immune checkpoint inhibitors (ICIs) has markedly altered the outcome patients with melanoma. However, despite significant successes, anecdotal evidence suggested that treatment responses AGMs significantly lower than other metastatic sites. We sought investigate whether having an AGM is associated outcomes and ICI dampened adrenal glands. Patients Methods:...
9536 Background: Myeloid-derived suppressor cells (MDSCs) are potent suppressors of antitumor immunity and commonly associated with poor outcomes in melanoma patients treated immune checkpoint inhibitors. Inducing the differentiation MDSCs using all-trans retinoic acid (ATRA) reduces MDSC frequency. This analysis seeks to assess safety efficacy combining ATRA pembrolizumab advanced patients. Methods: single arm, institution, phase I/II study (NCT03200847) enrolled 24 diagnosed stage IV...
e21593 Background: Patients with cutaneous (CM) or acral (AM) melanoma have high response rates to immune checkpoint blockade (ICB) therapies including anti-CTLA4, anti-PD1, and their combination. In contrast, patients mucosal (MM) uveal (UM) low ICB a poorer overall prognosis. this study, we analyzed transcriptomes identify potential mechanisms underlying resistance in MM UM. We also evaluated epigenetic modifying drugs as agents improve responses these patients. Methods: RNA sequencing was...
Abstract Introduction Easily measuring individual circadian timing is increasingly important to inform personalized chronotherapy, screen for disorders and misalignment, advance research. Findings from multiple studies show that transcriptomics a viable method estimate dim-light melatonin onset (DLMO), but no published omics-based findings have predicted offset (DLMOff), only one known study has used metabolomics predict DLMO. Here, we developed tested plasma metabolomics-based biomarker of...
Abstract While much of the research concerning factors associated with responses to immunotherapies focuses on contributions conventional peptide-specific T cells, role unconventional such as mucosalassociated invariant (MAIT) in human melanoma remains largely unknown. MAIT cells are innate-like expressing a semi-invariant cell receptor restricted non-classical MHC class I molecule MR1 presenting vitamin metabolites derived from bacteria. In this prospective clinical study, we sought...
Abstract Myeloid-derived suppressor cells (MDSCs) are potent suppressors of antitumor immunity and commonly associated with poor outcomes in melanoma patients treated immune checkpoint inhibitors. Inducing the differentiation MDSCs using all-trans retinoic acid (ATRA) alters their activity reduces MDSC frequency. This trial seeks to assess safety efficacy combining ATRA pembrolizumab metastatic patients. In 24 stage IV patients, treatment Q3W plus supplemental orally for three days...
<p>Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.</p>
<p>Supplementary figure 2. Changes in other clinical hematologic measures. Colored box denotes the time when patients were being treated with ATRA. * Denotes p < 0.05, ** 0.01, *** 0.001, **** 0.0001.</p>
<div>AbstractPurpose:<p>A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of combination all-trans retinoic acid (ATRA) with pembrolizumab in patients stage IV melanoma.</p>Patients Methods:<p>Anti–PD-1 naïve melanoma were treated plus supplemental ATRA for three days surrounding each first four infusions. The primary objective establish MTD recommended II dose (RP2D) combination. secondary objectives describe toxicity combined treatment...
<p>Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.</p>
<p>Supplementary figure 2. Changes in other clinical hematologic measures. Colored box denotes the time when patients were being treated with ATRA. * Denotes p < 0.05, ** 0.01, *** 0.001, **** 0.0001.</p>